We are live on ! Find out more
IBER

Ibere Pharmaceuticals
IBER

Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

46 hedge funds and large institutions have $103M invested in Ibere Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

2% less capital invested

Capital invested by funds: $105M → $103M (-$1.65M)

4% less funds holding

Funds holding: 48 → 46 (-2)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
46
Holders Change
-2
Holders Change %
-4.17%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
5
Increased
6
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$3.25M
2
PAMP
Polar Asset Management Partners
Ontario, Canada
+$1.75M
3
CF
Cantor Fitzgerald
New York
+$1.1M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1,000K
5
AA
AQR Arbitrage
Connecticut
+$981K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$5.39M
2
SCM
Shaolin Capital Management
Florida
-$1.96M
3
CCM
Context Capital Management
California
-$1.13M
4
ICMH
Integrity Capital Management (HK)
Hong Kong
-$458K
5
DFCM
Dark Forest Capital Management
Puerto Rico
-$224K
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
26
Walleye Capital
New York
$1.08M – – –
AA
27
AQR Arbitrage
Connecticut
$981K +$981K +100,000 New
FTCM
28
Fir Tree Capital Management
New York
$806K – – –
SCM
29
Saba Capital Management
New York
$785K – – –
Walleye Trading
30
Walleye Trading
New York
$785K – – –
WA
31
Whitebox Advisors
Minnesota
$738K – – –
WRBC
32
W.R. Berkley Corp
Connecticut
$675K – – –
Goldman Sachs
33
Goldman Sachs
New York
$549K – – –
LCM
34
Lynwood Capital Management
Ontario, Canada
$504K – – –
PI
35
PEAK6 Investments
Illinois
$490K – – –
Barclays
36
Barclays
United Kingdom
$481K +$481K +49,023 New
TCM
37
Tegean Capital Management
New York
$448K – – –
DMKJ
38
David M. Knott Jr
$353K – – –
Capstone Investment Advisors
39
Capstone Investment Advisors
New York
$245K – – –
DFCM
40
Dark Forest Capital Management
Puerto Rico
$212K -$224K -22,831 -51%
DIG
41
DeepCurrents Investment Group
New York
$174K – – –
EH
42
EMG Holdings
Connecticut
$98K – – –
RCM
43
Robinson Capital Management
Michigan
$94K -$81.6K -8,324 -47%
CI Investments Inc
44
CI Investments Inc
Ontario, Canada
$44K -$5.97K -609 -12%
UBS Group
45
UBS Group
Switzerland
$20K – – –
MF
46
Magnetar Financial
Illinois
$700 +$700K +71,382 New
SCC
47
Spring Creek Capital
Kansas
– -$3.92M -400,000 Closed
CCM
48
Context Capital Management
California
– -$1.13M -115,053 Closed
ICMH
49
Integrity Capital Management (HK)
Hong Kong
– -$458K -46,717 Closed
CSS
50
Cubist Systematic Strategies
Connecticut
– -$205K -20,870 Closed
1
2
3

IBER Hedge Fund Activity: Q2 2022 in Review

46 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q2 2022, worth a combined $103M — down 1.6% from $105M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of IBER and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 6 added.

The largest buyer was Glazer Capital LLC, adding an estimated $3.25M. The largest seller was Citadel Advisors, cutting an estimated $5.39M.

  • 46 institutional investors held Ibere Pharmaceuticals (IBER) as of Q2 2022, down from 48 in Q1 2022.
  • Funds reported $103M of Ibere Pharmaceuticals stock for Q2 2022, down 1.6% quarter-over-quarter.
  • 5 funds opened new Ibere Pharmaceuticals positions in Q2 2022 and 6 closed out, a net change of -1 holder.
  • The largest Ibere Pharmaceuticals buyer in Q2 2022 was Glazer Capital LLC, an estimated $3.25M added.
  • The largest Ibere Pharmaceuticals seller in Q2 2022 was Citadel Advisors, an estimated $5.39M sold.

Based on aggregated 13F filings for Q2 2022.